|
|
| | GSK2110183B Basic information |
| Product Name: | GSK2110183B | | Synonyms: | Afuresertib (hydrochloride);GSK 2110183B;GSK2110183B;GSK-2110183B;GSK 2110183 hydrochloride;GSK2110183 hydrochloride;GSK-2110183 hydrochloride;N-((S)-1-Amino-3-(3-fluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide hydrochloride | | CAS: | 1047645-82-8 | | MF: | C18H18Cl3FN4OS | | MW: | 463.78 | | EINECS: | | | Product Categories: | | | Mol File: | 1047645-82-8.mol |  |
| | GSK2110183B Chemical Properties |
| storage temp. | Store at -20°C, protect from light, stored under nitrogen | | solubility | DMSO:65.0(Max Conc. mg/mL);140.15(Max Conc. mM)
DMF:50.0(Max Conc. mg/mL);107.81(Max Conc. mM)
Ethanol:50.0(Max Conc. mg/mL);107.81(Max Conc. mM)
Ethanol:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.08(Max Conc. mM) | | form | A crystalline solid | | color | Yellow to brown |
| | GSK2110183B Usage And Synthesis |
| Uses | Afuresertib is a selective, orally bioavailable inhibitor of Akt1, 2, and 3 with Ki values of 0.08, 2, and 2.6 nM, respectively. It preferentially inhibits the proliferation of human cancer cell lines with Akt pathway activation and various cell lines derived from hematologic malignancies with minimal effect on glucose homeostasis. Afuresertib demonstrates activity against multiple myeloma in both preclinical and clinical models.[Cayman Chemical] |
| | GSK2110183B Preparation Products And Raw materials |
|